10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||
| ||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ABBVIE INC. | |||
Ticker: ABBV Fiscal Year: 2021 | |||
Consolidated Statements of Earnings | |||
Period Ending Dec 31, 2021 10-K (Filed: Feb 18, 2022) | |||
| (In Millions) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
| Net revenues | $ 56,197 | 45,804 | 33,266 |
| Cost of products sold | 17,446 | 15,387 | 7,439 |
| Selling, general and administrative | 12,349 | 11,299 | 6,942 |
| Research and development | 7,084 | 6,557 | 6,407 |
| Acquired in-process research and development | 962 | 1,198 | 385 |
| Other operating expense (income), net | 432 | 0 | (890) |
| Total operating costs and expenses | 38,273 | 34,441 | 20,283 |
| Operating earnings | 17,924 | 11,363 | 12,983 |
| Interest expense, net | 2,384 | 2,280 | 1,509 |
| Net foreign exchange loss | 51 | 71 | 42 |
| Other expense, net | 2,500 | 5,614 | 3,006 |
| Earnings before income tax expense | 12,989 | 3,398 | 8,426 |
| Income tax expense (benefit) | 1,440 | (1,224) | 544 |
| Net earnings | 11,549 | 4,622 | 7,882 |
| Net earnings attributable to noncontrolling interest | 7 | 6 | 0 |
| Net earnings attributable to AbbVie Inc. | 11,542 | 4,616 | 7,882 |
| Per share data | |||
| Basic earnings per share (in dollars per share) | 6.48 | 2.73 | 5.30 |
| Diluted earnings per share (in dollars per share) | 6.45 | 2.72 | 5.28 |
| Weighted-average basic shares outstanding (in shares) | 1,770 | 1,667 | 1,481 |
| Weighted-average diluted shares outstanding (in shares) | 1,777 | 1,673 | 1,484 |
| External Links | |
| ABBVIE INC. (ABBV) Fiscal Year 2021 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |